Michael Cherny
Stock Analyst at Leerink Partners
(5.00)
# 7
Out of 4,896 analysts
112
Total ratings
58.33%
Success rate
133.85%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGNY Progyny | Upgrades: Outperform | $28 | $23.08 | +21.32% | 11 | Jul 8, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $165 → $170 | $161.22 | +5.45% | 12 | Jun 10, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.18 | +154.24% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $709.55 | +12.75% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.33 | +13.13% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $323.80 | +1.91% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $48.08 | -16.81% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $64.71 | +15.90% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $60.09 | +49.78% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $202.05 | +38.58% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $168.18 | +3.46% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $73.56 | +14.19% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $163.28 | +51.89% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $150.76 | +69.14% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.26 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $295.33 | -6.88% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.52 | +91.06% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $248.90 | +4.46% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $21.12 | +6.56% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.75 | +68.42% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.17 | +70.10% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $8.31 | +104.57% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $5.93 | +785.33% | 2 | Jan 5, 2022 |
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $23.08
Upside: +21.32%
Cardinal Health
Jun 10, 2025
Maintains: Buy
Price Target: $165 → $170
Current: $161.22
Upside: +5.45%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.18
Upside: +154.24%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $709.55
Upside: +12.75%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.33
Upside: +13.13%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $323.80
Upside: +1.91%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $48.08
Upside: -16.81%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $64.71
Upside: +15.90%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $60.09
Upside: +49.78%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $202.05
Upside: +38.58%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $168.18
Upside: +3.46%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $73.56
Upside: +14.19%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $163.28
Upside: +51.89%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $150.76
Upside: +69.14%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.26
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $295.33
Upside: -6.88%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.52
Upside: +91.06%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $248.90
Upside: +4.46%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $21.12
Upside: +6.56%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.75
Upside: +68.42%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.17
Upside: +70.10%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $8.31
Upside: +104.57%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $5.93
Upside: +785.33%